Long-term benefit of the TAXUS liberté stent in small vessels and long lesions - TAXUS ATLAS program

Circulation Journal

Volumn 75, Issue 5, 2011, Pages 1120-1129

  Ormiston, John A ^a   Turco, Mark A ^b   Hall, Jack J ^c   Cannon, Louis A ^d   Yakubov, Steven J ^e   Lucca, Michael J ^f   Stone, Gregg W ^g   O'Shaughnessy, Charles D ^h   Kozina, Joseph A ⁱ   Gilchrist, Ian C ^j   Bertolet, Barry D ^k   Worthley, Stephen G ^l   Underwood, Paul L ^m   Dawkins, Keith D ^m  

^a Mercy Hospital   (New Zealand)

^b WASHINGTON ADVENTIST HOSPITAL   (United States)

^c ST VINCENT HOSPITAL   (United States)

^d Northern Michigan Regional Health Systems   (United States)

^e RIVERSIDE METHODIST HOSPITAL   (United States)

^f Duluth Clinic   (United States)

^g Department of Medicine   (United States)

^h Elyria Memorial Hospital   (United States)

ⁱ Mercy General Hospital   (United States)

^j PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^k Cardiology Associates of North Mississippi   (United States)

^l UNIVERSITY OF ADELAIDE   (Australia)

^m BOSTON SCIENTIFIC CORPORATION   (United States)

more..

Author keywords

Paclitaxel eluting stent; Stent designs; Stent thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PACLITAXEL; THIENOPYRIDINE DERIVATIVE; TICLOPIDINE;

ARTICLE; BLOOD VESSEL DIAMETER; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DRUG ELUTING STENT; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; Q WAVE; QUANTITATIVE ANALYSIS; RESTENOSIS; STABLE ANGINA PECTORIS; STENT THROMBOSIS; THROMBOSIS;

HUMANS; STENTS; TAXUS;

EID: 79955702491     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0848     Document Type: Article

References (33)

1. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents: A hierarchical Bayesian meta-analysis. Ann Intern Med 2003; 138: 777-786.
2. Turco MA, Ormiston JA, Popma JJ, Mandinov L, O'Shaughnessy CD, Mann T, et al. Polymer-based, paclitaxel-eluting TAXUS Liberte stent in de novo lesions: The Pivotal TAXUS ATLAS Trial. J Am Coll Cardiol 2007; 49: 1676-1683.
3. Turco MA, Ormiston JA, Popma JJ, Hall JJ, Mann T, Cannon LA, et al. Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: 1-year results from the TAXUS ATLAS program. J Am Coll Cardiol Interv 2008; 1: 699-709.
4. Windecker S, Meier B. Late coronary stent thrombosis. Circulation 2007; 116: 1952-1965.
5. Räber L. SIRTAX-LATE: 5 year clinical and angiographic followup from a prospective, randomized trial comparing sirolimus-eluting with paclitaxel-eluting stents. In: Proceedings of Transcatheter Cardiovascular Therapeutics 2009, San Francisco, CA, USA.
6. Claessen BE, Beijk MA, Legrand V, Ruzyllo W, Manari A, Varenne O, et al. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: The SPIRIT II Trial. Circ Cardiovasc Interv 2009; 2: 339-347.
7. Aoki J, Abizaid AC, Serruys PW, Ong ATL, Boersma E, Sousa JE, et al. Evaluation of four-year coronary artery response after sirolimus-eluting stent implantation using serial quantitative intravascular ultrasound and computer-assisted grayscale value analysis for plaque composition in event-free patients. J Am Coll Cardiol 2005; 46: 1670-1676.
8. Goto K, Shiode N, Shirota K, Fukuda Y, Kitamura F, Tominaga K, et al. Pathological finding of sirolimus-eluting stent (SES) restenosis lesion with black hole appearance on intravascular ultrasound. Circ J 2009; 73: 1969-1971.
9. Ellis SG, Stone GW, Cox DA, Hermiller J, O'Shaughnessy C, Mann T, et al. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV Clinical Trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). J Am Coll Cardiol Interv 2009; 2: 1248-1259.
10. Ellis SG, Cannon LA, Mann T, Cambier PA, O'Shaughnessy CD, DeMaio S, et al. Final five-year outcomes from the TAXUS V de novo trial: Long-term safety and effectiveness of the paclitaxeleluting TAXUS stent in complex lesions. Am J Cardiol 2009; 104: 135D.
11. Grube E, Dawkins K, Guagliumi G, Banning A, Zmudka K, Colombo A, et al. TAXUS VI final 5-year results: A multicentre, randomised trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary artery lesions. EuroIntervention 2009; 4: 572-577.
12. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.
13. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial. JAMA 2005; 294: 1215-1223.
14. Ormiston JA, Mahmud E, Turco MA, Popma JJ, Weissman N, Cannon LA, et al. Direct stenting with the TAXUS Liberté drugeluting stent: Results from the TAXUS ATLAS DIRECT STENT Study. J Am Coll Cardiol Interv 2008; 1: 150-160.
15. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
16. Beiser A, D'Agostino RB Sr, Seshadri S, Sullivan LM, Wolf PA. Computing estimates of incidence, including lifetime risk: Alzheimer's disease in the Framingham Study: The Practical Incidence Estimators (PIE) macro. Stat Med 2000; 19: 1495-1522.
17. Chacko R, Mulhearn M, Novack V, Novack L, Mauri L, Cohen SA, et al. Impact of target lesion and nontarget lesion cardiac events on 5-year clinical outcomes after sirolimus-eluting or bare-metal stenting. J Am Coll Cardiol Interv 2009; 2: 498-503.
18. Leon MB, Allocco DJ, Dawkins KD, Baim DS. Late clinical events after drug-eluting stents: The interplay between stent-related and natural history-driven events. J Am Coll Cardiol Intervv 2009; 2: 504-512.
19. Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schomig A, et al. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 2006; 27: 260-266.
20. Menozzi A, Solinas E, Ortolani P, Repetto A, Saia F, Piovaccari G, et al. Twenty-four months clinical outcomes of sirolimus-eluting stents for the treatment of small coronary arteries: The long-term SES-SMART clinical study. Eur Heart J 2009; 30: 2095-2101.
21. Raisuke I, Yuji I, Akiyoshi M, Hiroyoshi N, Kazuhiro H. Predictors of restenosis after implantation of 2.5 mm stents in small coronary arteries. Circ J 2004; 68: 236-240.
22. Briguori C, Sarais C, Pagnotta P, Liistro F, Montorfano M, Chieffo A, et al. In-stent restenosis in small coronary arteries: Impact of strut thickness. J Am Coll Cardiol 2002; 40: 403-409.
23. Kastrati A, Mehilli J, Dirschinger J, Dotzer F, Schuhlen H, Neumann FJ, et al. Intracoronary stenting and angiographic results: Strut Thickness Effect on Restenosis Outcome (ISAR-STEREO) Trial. Circulation 2001; 103: 2816-2821.
24. Inoue T, Node K. Molecular basis of restenosis and novel issues of drug-eluting stents. Circ J 2009; 73: 615-621.
25. Kereiakes DJ, Cannon LA, Feldman RL, Popma JJ, Magorien R, Whitbourn R, et al. Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: Primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS Element Paclitaxel-Eluting Coronary Stent System) Trial. J Am Coll Cardiol 2010; 56: 264-271.
26. Hausleiter J, Kastrati A, Mehilli J, Schühlen H, Pache J, Dotzer F, et al. Impact of lesion complexity on the capacity of a trial to detect differences in stent performance: Results from the ISAR-STEREO trial. Am Heart J 2003; 146: 882-886.
27. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
28. Honda Y. Drug-eluting stents: Insights from invasive imaging technologies. Circ J 2009; 73: 1371-1380.
29. Takano M, Inami S, Jang IK, Yamamoto M, Murakami D, Seimiya K, et al. Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent three months after implantation. Am J Cardiol 2007; 99: 1033-1038.
30. Weissman NJ, Turco M, Ormiston J, Mandinov L, Mann JT, Cannon L, et al. Intravascular ultrasound assessment of TAXUS Liberté performance in two TAXUS ATLAS Trials. Am J Cardiol 2007; 100: 120L.
31. Farb A, Burke AP, Kolodgie FD, Virmani R. Pathological mechanisms of fatal late coronary stent thrombosis in humans. Circulation 2003; 108: 1701-1706.
32. Simon C, Palmaz JC, Sprague EA. Influence of topography on endothelialization of stents: Clues for new designs. J Long Term Effect Med Implants 2000; 10: 143-151.
33. Kedhi E, Joesoef KS, McFadden E, Wassing J, van Mieghem C, Goedhart D, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): A randomized trial. Lancet 2010; 375: 201-209.